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Mayo every 4 wk (loss of response was confirmed by endoscopy); 
patients who maintained response through wk 54 were considered 
to be in CCR.[1] Our current analysis sought to identify early pre-
dictors of CCR.
Methods: This post hoc analysis included 456 patients from 
PURSUIT who were responders at wk 6 after golimumab induction 
and entered maintenance treatment.[2] Potential predictors evalu-
ated were age; gender; disease duration (≤5y vs >5y); disease extent 
(extensive vs limited); Mayo score at induction wk 0 (<9 vs ≥9); 
Mayo score at induction wk 6; stool frequency and rectal bleed-
ing (Mayo) at induction wk 6; CRP, calprotectin, and lactoferrin at 
induction wk 6 and change from induction wk 0-6; Mayo change 
from induction wk 0-6; CRP normalization at induction wk 6; 
mucosal healing (Mayo endoscopy score 0 or 1) at induction wk 6; 
and golimumab maintenance vs withdrawal. Potential interactions 
between factors were evaluated. Final stepwise selection of terms 
was used with significance levels for entry and retention of 0.50 and 
0.15, respectively.
Results: In univariate analysis, factors significantly associated with 
CCR were treatment group, wk-6 fecal calprotectin, and wk-6 
lactoferrin. Wk-6 calprotectin and lactoferrin were correlated 
(r=0.78; P<.0001). results of the final multivariable model are 
shown in Table.
Conclusions: In this post hoc analysis of PURSUIT, maintenance 
treatment with golimumab and wk-6 calprotectin levels were sig-
nificant predictors of CCR in moderate to severe UC patients who 
responded to golimumab induction at wk 6.
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Background: To characterize and analyze in the Swiss IBD Cohort 
: a) reported Azathioprine (AZA) and 6-Mercaptopurine (6-MP) 
adverse effects (AE), b) causes of discontinuation and c) response 
to therapy according to gastroenterologists' clinical judgment, d) 
whether level of 6-TGN < 235pmol/8 x108 red blood cells (RBC) is 
associated with a higher risk of "flare" occurrence.
Methods: Retrospective statistical description, Cox model and 
Kaplan-Meier survival estimation.
Results: 1499 patients with Crohn's Disease (CD) and 1066 with 
Ulcerative colitis (UC).
a) Of 1670 patients ever treated with AZA/6-MP, there were 611 
reported AE: 149 intolerances are observed (24.4%), 81 pancreatitis 
(13.2%), 61 hepatitis (10.0%), 33 hematologic side effects (5.4%), 
20 hypersensitivities (3.2%), 17 infections (2.8%), 13 cases of fatigue 
(2.1%), 7 malignancies (1.2%) and 207 not further specified AE 
(33.9%).
b) Of 566 reported causes of discontinuation according to gastro-
enterologists' clinical judgment, 209 "treatment no long needed" 
(36.9%), 196 "breakthrough/loss of response (34.6%), 92 "patient 
wish" (16.3%), 45 "primary non-response" (7.9%) and 21 
"Conception/Pregnancy or wish of it" (3.7%) were described.
c) Of 1187 gastroenterologists' clinical judgment of AZA/6-MP 
responses, 417 (35%) were judged as "successful", 639 (54%) as 
"failure", 131 (11%) "unknown".
d) Of 364 CD patients under AZA/6-MP, 199 (54.7%) developed a 
"flare" during the observation period (median 13.3 mo, IQR 11.9-
23.4, range 5.8-59.0). Of 204 patients with UC under AZA/6-MP, 
106 (52.0%) developed a "flare" during the observation period 
(median 14.0 mo, IQR 12.2-24.9, range 7.3-48.2). 6-TGN levels ≥ 
235 pmol/8 x 108 RBC showed a not statistically significant tendency 
to improve "flare"-free survival time in CD and UC (HR=1.157, 
95CI: 0.680-1.971, p=0.590).
Conclusions: In the SIBDC, AZA/6-MP are frequently used, AE and 
failure are frequently reported, 6-TGN levels ≥ 235 showed a ten-
dency to improve "flare"-free survival.
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Table. Multivariable Model Predicting Continuous Clinical 
Response.
Predictor Odds Ratio 95% Confidence Interval P-value
Calprotectin 
wk 6 (log)
0.55 0.394–0.775 .0006
Calprotectin 
change from 
wk 0–6 (log)
1.34 0.989–1.810 .0587
Treatment 
(golimumab 
maintenance vs 
withdrawal)
1.91 1.234–2.957 .0037
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